Key Highlights
- Shares of Butterfly Network rallied approximately 31% following Midjourney’s introduction of Midjourney Medical and its innovative full-body ultrasonic scanner
- Each scanner prototype incorporates 40 Ultrasound-on-Chip modules from Butterfly, part of a co-development partnership valued at up to $74 million spanning five years
- TD Cowen’s Joshua Jennings highlighted that this partnership validates Butterfly’s chip-licensing model as a viable independent revenue channel
- Midjourney’s ambitious roadmap includes 5,000 spa facilities and over 50,000 deployed scanners globally by 2031, potentially generating substantial chip orders for Butterfly
- Analysts at William Blair raised concerns about regulatory clearance timelines, reimbursement pathways, and the clinical evidence supporting routine whole-body imaging
Shares of Butterfly Network (BFLY) climbed to $7.54 on Thursday, gaining approximately 31% after Midjourney formally announced its healthcare venture alongside a medical device powered by Butterfly’s proprietary technology.
Midjourney Medical introduced the Midjourney Scanner — a revolutionary full-body ultrasonic computational tomography system. Each existing prototype integrates 40 of Butterfly’s specialized Ultrasound-on-Chip imaging modules, with plans to incorporate additional modules in subsequent iterations.
The revelation pushed BFLY to an intraday 52-week peak of $8.01, marking a significant jump from the previous closing price of $5.71.
This collaboration operates through Butterfly Embedded, the company’s chip-licensing division previously operating as Octiv. According to an SEC filing from November 2025, Butterfly expects to receive up to $74 million in total payments throughout the five-year partnership term.
Elon Musk commented on the news via X with a brief “cool,” amplifying social media buzz around the announcement and sustaining investor interest during trading hours.
With short interest hovering around 12.6% of the float before Thursday’s session, the rapid unwinding of bearish bets contributed additional momentum to the stock’s upward trajectory.
Analyst Perspectives on the Deal
Joshua Jennings from TD Cowen was quick to emphasize the strategic significance of this partnership. He contended that the collaboration demonstrates the standalone commercial potential of Butterfly’s chip technology separate from its handheld ultrasound products — establishing pathways for licensing fees, chip volume sales, and revenue-sharing arrangements.
William Blair analysts also provided commentary, characterizing Midjourney’s deployment strategy as a potentially significant long-term growth driver for Butterfly.
Midjourney’s expansion blueprint calls for 5,000 specialized “Midjourney Spas,” each operating approximately 10 scanning units. The inaugural facility is slated to launch in San Francisco during late 2027.
Additionally, the company is developing advanced scanner models scheduled for 2028 release, targeting a worldwide installed base exceeding 50,000 units by 2031. With approximately 40 chips required per scanner, William Blair analysts noted this represents considerable revenue potential for Butterfly’s semiconductor division.
Lingering Uncertainties
Not all market observers share the same optimism. William Blair’s Andrew Brackmann identified several unresolved issues that could influence the partnership’s ultimate success.
He questioned whether Midjourney can secure FDA clearance rapidly enough to support such aggressive deployment targets. Reimbursement from insurance providers presents another significant obstacle — Brackmann emphasized that coverage decisions will be essential to realizing the addressable market opportunity.
Brackmann also observed the current absence of preliminary clinical data from the scanner demonstrating meaningful benefits for routine whole-body screening applications.
Butterfly’s leadership team, including CEO Joe DeVivo, CFO John Doherty, and SVP of Innovation David Horsley, participated in a TD Cowen Medical Devices Emerging Growth conference call at noon ET Thursday.
Market conditions were favorable during the session, with the S&P 500 advancing 0.9% and the Nasdaq climbing 1.2%.
At the time of publication, BFLY was trading at $7.49, representing a 31.1% increase.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
